SRRK Stock Forecast & Price Target

Scholar Rock Holding is supported by a broadened FDA-approved label for ISEMBYLD in SMA, which covers adults and children two years of age and older across subtypes and ambulatory status, helping open access to roughly 6,600 U.S. patients on SMN2-targeted therapy. The positive Phase 3 SAPPHIRE data, including a 2.2-point HFMSE improvement, plus ~98% retention into ONYX and management’s expectation of about $310K in annual net revenue per typical patient, strengthen confidence in a durable launch and a path toward blockbuster potential. Concern around fracture language appears unlikely to materially restrain prescribing, while a concentrated commercial footprint with about 140 treatment centers and 2,600 prescribers, along with pipeline optionality from apitegromab expansion and SRK-439, supports longer-term value creation.

Scholar Rock Holding is viewed negatively because payer acceptance for Isembyld may be weaker than for SMN modifiers, as insurers could question reimbursement for a drug that is not preserving motor neurons and therefore may face duration and access risk. The clinical value proposition also looks limited, with one KOL describing the SAPPHIRE motor-scale gains as “on the smaller end of significance” and noting that patients may hesitate to trade a roughly 2-point improvement for monthly IV infusions. Even among older, more stable patients, adoption may be delayed rather than immediate, reinforcing concerns that the therapy’s modest effect size and treatment burden could constrain commercial uptake.